Alimera Sciences Inc (ALIM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
49
About the Report
About the Report
Summary
Alimera Sciences Inc (Alimera) is a biopharmaceutical company that researches, develops and commercializes prescription ophthalmic pharmaceuticals. The company's products include Iluvien, an intravitreal implant of fluocinolone acetonide which is indicated for the treatment of chronic diabetic macular edema (DME) in patients who have been previously treated with corticosteroids and did not show any clinically significant increase in intraocular pressure (IOP). Iluvien is also prescribed for treatment of early-and late-stage diseases such as wet and dry age-related macular degeneration (AMD) and retinal vein occlusion. The company distributes its products in France, Austria, Portugal, the Czech Republic, Denmark, Finland, Germany, Spain, the UK and others. Alimera is headquartered in Alpharetta, Georgia, the US.
Alimera Sciences Inc (ALIM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Alimera Sciences Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alimera Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Alimera Sciences Inc, Medical Devices Deals, 2012 to YTD 2018 9
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Alimera Sciences Enters into Distribution Agreement with Horus Pharma 11
Alimera Sciences Enters into Distribution Agreement with Brill Pharma 12
Alimera Sciences Enters into Distribution Agreement with MEAgate 13
Alimera Sciences Enters into Distribution Agreement with SIFI for Iluvien 14
Alimera Sciences Enters into Distribution Agreement with Knight Therapeutics 15
Alimera Sciences Enters Into Distribution Agreement With Specialised Therapeutics For Iluvien 16
Equity Offering 17
Alimera Sciences Plans to Raise up to USD100 Million in Public Offering of Securities 17
Alimera Sciences Raises USD1.2 Million in Public Offering of Shares 18
Alimera Sciences Raises USD26.5 Million in Public Offering of Shares 19
Alimera Sciences Raises USD0.8 Million in Private Placement of Shares 21
Alimera Sciences Raises USD50 Million in Private Placement of Preferred Stock 22
Alimera Sciences Raises USD35 Million in Public Offering of Shares 24
Alimera Sciences Completes Private Placement Of Shares For USD 37.5 Million 25
Alimera Sciences Completes Private Placement Of Units For USD 40 Million 26
Acquisition 28
Alimera Sciences Mulls for Sale 28
Alimera Sciences Inc-Key Competitors 29
Alimera Sciences Inc-Key Employees 30
Alimera Sciences Inc-Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Nov 05, 2018: Alimera Sciences reports third quarter 2018 results 32
Jul 31, 2018: Alimera Sciences Reports Second Quarter 2018 Results 34
May 02, 2018: Alimera Sciences Reports First Quarter 2018 Results 36
Feb 28, 2018: Alimera Sciences Reports Fourth Quarter and Full Year 2017 Financial Results 38
Nov 01, 2017: Alimera Sciences Reports Third Quarter 2017 Financial Results 40
Aug 02, 2017: Alimera Sciences Reports Second Quarter 2017 Financial Results 42
May 08, 2017: Alimera Sciences Reports First Quarter 2017 Financial Results 44
Mar 01, 2017: Alimera Sciences Reports Record Fourth Quarter and Full Year 2016 Financial Results 46
Corporate Communications 48
Jun 21, 2018: Alimera Sciences Names Mary T. Szela As Board Director 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49
List of Figure
List of Figures
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Alimera Sciences Inc, Medical Devices Deals, 2012 to YTD 2018 9
List of Table
List of Tables
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Alimera Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Alimera Sciences Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Alimera Sciences Inc, Medical Devices Deals, 2012 to YTD 2018 9
Alimera Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Alimera Sciences Enters into Distribution Agreement with Horus Pharma 11
Alimera Sciences Enters into Distribution Agreement with Brill Pharma 12
Alimera Sciences Enters into Distribution Agreement with MEAgate 13
Alimera Sciences Enters into Distribution Agreement with SIFI for Iluvien 14
Alimera Sciences Enters into Distribution Agreement with Knight Therapeutics 15
Alimera Sciences Enters Into Distribution Agreement With Specialised Therapeutics For Iluvien 16
Alimera Sciences Plans to Raise up to USD100 Million in Public Offering of Securities 17
Alimera Sciences Raises USD1.2 Million in Public Offering of Shares 18
Alimera Sciences Raises USD26.5 Million in Public Offering of Shares 19
Alimera Sciences Raises USD0.8 Million in Private Placement of Shares 21
Alimera Sciences Raises USD50 Million in Private Placement of Preferred Stock 22
Alimera Sciences Raises USD35 Million in Public Offering of Shares 24
Alimera Sciences Completes Private Placement Of Shares For USD 37.5 Million 25
Alimera Sciences Completes Private Placement Of Units For USD 40 Million 26
Alimera Sciences Mulls for Sale 28
Alimera Sciences Inc, Key Competitors 29
Alimera Sciences Inc, Key Employees 30
Alimera Sciences Inc, Subsidiaries 31
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.